PTK787/ZK222584 [vatalinib] and RAD001 [everolimus] for patients with advanced solid tumors.

Trial Profile

PTK787/ZK222584 [vatalinib] and RAD001 [everolimus] for patients with advanced solid tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Everolimus (Primary) ; Vatalanib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 May 2008 The expected completion date for this trial is now 1 Aug 2009.
    • 04 May 2008 Status changed from recruiting to in progress on ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top